Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Here are some of the stocks making notable moves in Wednesday's premarket action: Dynavax Technologies stock is up 37% after ...

Shares of Dynavax Technologies (NASDAQ: DVAX) popped on Wednesday after the vaccine maker struck a deal to be acquired by ...

Sanofi agreed to buy vaccine specialist Dynavax Technologies in a $2.2 billion cash deal, turning to dealmaking in a bid to ...

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Dynavax Technologies Corp. (NASDAQ:DVAX) is one of the best performers on Wednesday. Dynavax soared by 38.19 percent on Wednesday ...

If you are wondering whether Dynavax Technologies at around $15 a share is still good value after its run, you are not alone. We are going to unpack that in a structured way. The stock has surged 42.5 ...

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.

Sanofi announced that it has entered into an agreement to acquire Dynavax Technologies Corporation (Dynavax), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (Heplisav-B) ...

Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...

French pharmaceutical giant Sanofi has announced plans to acquire U.S.-based biotech company Dynavax Technologies in a deal ...

Sanofi acquires Dynavax for $2.2B, gaining Heplisav-B and promising vaccine pipeline. Click here to read my analysis of SNY stock and the DVAX acquisition.